JP2021516966A5 - - Google Patents

Info

Publication number
JP2021516966A5
JP2021516966A5 JP2020546981A JP2020546981A JP2021516966A5 JP 2021516966 A5 JP2021516966 A5 JP 2021516966A5 JP 2020546981 A JP2020546981 A JP 2020546981A JP 2020546981 A JP2020546981 A JP 2020546981A JP 2021516966 A5 JP2021516966 A5 JP 2021516966A5
Authority
JP
Japan
Prior art keywords
anchor domain
fusion protein
binding
seq
polypeptide
Prior art date
Application number
JP2020546981A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019173829A5 (https=
JP2021516966A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021639 external-priority patent/WO2019173829A1/en
Publication of JP2021516966A publication Critical patent/JP2021516966A/ja
Publication of JPWO2019173829A5 publication Critical patent/JPWO2019173829A5/ja
Publication of JP2021516966A5 publication Critical patent/JP2021516966A5/ja
Pending legal-status Critical Current

Links

JP2020546981A 2018-03-09 2019-03-11 組織への生物学的薬物の送達 Pending JP2021516966A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862640859P 2018-03-09 2018-03-09
US62/640,859 2018-03-09
PCT/US2019/021639 WO2019173829A1 (en) 2018-03-09 2019-03-11 Delivering biological drugs to tissues

Publications (3)

Publication Number Publication Date
JP2021516966A JP2021516966A (ja) 2021-07-15
JPWO2019173829A5 JPWO2019173829A5 (https=) 2022-03-18
JP2021516966A5 true JP2021516966A5 (https=) 2022-03-18

Family

ID=67846359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020546981A Pending JP2021516966A (ja) 2018-03-09 2019-03-11 組織への生物学的薬物の送達

Country Status (5)

Country Link
US (1) US11529389B2 (https=)
EP (1) EP3762429A4 (https=)
JP (1) JP2021516966A (https=)
AU (1) AU2019231307A1 (https=)
WO (1) WO2019173829A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2695161T3 (es) * 2011-12-14 2019-01-02 Univ Arkansas Administración de agentes terapéuticos mediante una proteína de unión a colágeno
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
LU101758B1 (en) * 2020-04-28 2021-10-28 Microsoft Technology Licensing Llc Digital wallet as a relying party in a decentralized network
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
US20040224010A1 (en) 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
US20050027110A1 (en) * 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system
JP3885077B2 (ja) 2004-03-26 2007-02-21 独立行政法人科学技術振興機構 三次元ディスプレイ
US9187517B2 (en) 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
US9309313B2 (en) 2008-01-09 2016-04-12 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
BR112012001977A2 (pt) 2009-07-29 2017-01-31 Glaxo Group Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar.
WO2012082659A1 (en) * 2010-12-13 2012-06-21 Cress Jonathan H Disposable dispenser drop diverter
ES2720659T3 (es) 2011-02-15 2019-07-23 Vaxiion Therapeutics Llc Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos
ES2695161T3 (es) 2011-12-14 2019-01-02 Univ Arkansas Administración de agentes terapéuticos mediante una proteína de unión a colágeno
US9890378B2 (en) 2012-05-11 2018-02-13 Merck Sharp & Dohme Corp. Surface anchored light chain bait antibody display system
EP2864360B1 (en) 2012-06-25 2017-09-06 The Brigham and Women's Hospital, Inc. Targeted therapeutics
WO2014089267A1 (en) 2012-12-05 2014-06-12 Eleven Biotherapeutics, Inc. Galectin-3 fusion proteins
WO2014096028A1 (en) 2012-12-19 2014-06-26 Glaxo Group Limited Guide device for a liquid dispenser
HRP20251426T1 (hr) * 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2014197485A1 (en) 2013-06-03 2014-12-11 Ansun Biopharma, Inc. Anti-viral therapeutic for infection of the eye
US9416197B2 (en) 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
CA2968141C (en) * 2015-01-16 2020-08-04 Hsing-Mao CHU Molecular constructs with targeting and effector elements
US10925972B2 (en) 2015-05-01 2021-02-23 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
EP3516063A4 (en) 2016-09-20 2020-05-13 University of Pittsburgh- Of the Commonwealth System of Higher Education USE OF PROTEIN-BASED MEDICINES WITH AN ANCHOR DOMAIN FOR USE ON THE EYE SURFACE

Similar Documents

Publication Publication Date Title
JP2021516966A5 (https=)
US7582288B2 (en) Methods of targeting multiple cytokines
EP2016098B1 (en) Antibody-targeted cytokines for therapy
CN103201284B (zh) 用于癌症和慢性感染的治疗的具有激动剂活性的衍生自il-2的多肽
Strober et al. The interleukins
CN103079586B (zh) G‑csf二聚体在治疗嗜中性粒细胞减少症中的应用
JPWO2019157224A5 (https=)
JP2020501510A5 (https=)
JP2021533204A5 (https=)
US10703799B2 (en) IL-33R and IL-1RAcP fusion proteins
Frieri Corticosteroid effects on cytokines and chemokines
Kusters et al. Cytokines and immune responses in murine atherosclerosis
JPWO2019173829A5 (https=)
TW570801B (en) Osteoclastgenic inhibitory agent
CN112135623B (zh) 与疾病的治疗有关的组合物和方法
Wanebo Tumor necrosis factors
Kolls et al. Recombinant cytokines and pulmonary host defense
Bendtzen et al. Naturally occurring autoantibodies to interleukin-1α, interleukin-6, interleukin-10, and interferon-α
Fujisawa et al. A synthetic peptide inhibitor for α-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice
AU637909B2 (en) Medical uses of m-csf
US20260028397A1 (en) Methods of treating ankylosing spondylitis
Saiki et al. Antimetastatic effect of endogenous tumor necrosis factor induced by the treatment of recombinant interferon γ followed by an analogue (GLA-60) to synthetic lipid A subunit
CN106349393B (zh) 一种增强抗体药物稳定性的结构
Lindley Interleukin-8
WO2023196916A1 (en) Methods of treating of hidradenitis suppurativa